Open Access
Subscription Access
Open Access
Subscription Access
Banned Medicines Menace: a Peril to Public Health
Subscribe/Renew Journal
Medical tourism and pharmaceutical boom are remarkable achievements of India over other countries due to hospitality, low cost quality treatment plans, easy research methodologies & less medico legal implications. Despite such major global responsibility, India is becoming a hub for the availability and usage of banned medicines. The proliferation of banned and harmful drugs in India is a serious problem for the health of people and there is an urgent need to curb it. A drug is banned on the basis of risk versus benefit ratio which is evaluated through post marketing surveillance and adverse drug reaction reporting systems. The medicines which have been labeled as silent killers overseas are making their space in India, indicating lack of knowledge among doctors and inefficient government policies. Drugs play a crucial role in saving lives, restoring health, preventing diseases and epidemics. When drug itself is harmful, it poses additive danger to the patient. Availability of such medicines over the counter is a grave problem. Medical profession is getting defamed and crippled in India because of various factors like self medication, unethical drug promotion, medical commercialization and unawareness among doctors. Until such issues are not sorted out the existing situation would prevail.
Keywords
Drug Development, Adverse Drug Reaction, Banned Medicines, Ayurvedic Medicine, Heavy Metals
Subscription
Login to verify subscription
User
Font Size
Information
- Shiva M, Rane W, Hansson Olle. In: Banned & bannable drugs- unbiased drug information essential drugs and rational drug policy. 5th edi. New Delhi (India): Voluntary Health Association of India (VHAI); 2004. p 7.
- Joshi B, Gupta G, Gupta N, Gupta M,Trivedi S, Patil P, Jhadav A,Vamsi K.K, Khairnar Y, Boraste A. Mujapara. Protein Based Drug Discovery. International Journal of Drug Discovery 2009; 1: 40-51.
- Guidance for Institutional Review Boards and Clinical Investigators. Food and Drug Administration. 1999-03-16. Retrieved 2007- 03-27.
- Thawani V, Sharma S, Gharpure K. Pharmacovigilance: Is it possible if bannable medicines are available over the counter?. Indian J Pharmacol 2005; 37:191.
- Leon S, Mutnick H. A, Souney F. P, Swanson N. L .Comprehensive Pharmacy Review, Sixth Edition. Published by: Wolter’s Kluwer Health Lippincott, Williams & Wilkins ©2007; ISBN: 0-7817-6561.
- Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229–2232.
- Adverse Event Reporting System (AERS) U.S food and drug administration: http:// www.hhs.gov/Last Updated: 08/20/2009.
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program: www.medwatch.com.
- Angell, Marcia (2009), “Drug Companies & Doctors: A Story of Corruption”, New York Review of Books 2009; 56.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of advese drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200–5.
- Burgio G.R. The Thalidomide disaster briefly revisited. Eur J Pediatr 1981; 136:229-230.
- Francis P A. Nimesulide: The End Begins. Thursday, June 05, 2003: www. pharmabiz.com.
- Thawani V, Sontakke S et al. Correspondence Indian journal of pharmacology 2003; 35:121-22.
- Rajwadkar K. Pediatric Nimesulide withdrawn from market. The Indian express (Nagpur) 2003 Jan 2; p13.
- Khan RA, Rahman SZ. A Case Report on Nimesulide and its Relation with Angina. J Pharmacovigilance Drug Safety 2004; 1: 19–21.
- Belton O, Byrne D, Kearney D. Cyclooxygenase- 1 and -2–Dependent Prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-845.
- Banned Drugs NEW, CiteMan_Newsletter@citemailer.com
- Shankar R. DCGI to ban nimesulide, cisapride, phenylpropanolamine and human placenta extracts soon. Pharmaceuticals Export Promotion Council(Pharmexcil). 13 Jan 2011.info@pharmexcil.com
- Vicks Action 500 & Nimesulide May Be Banned, http://www.india-server.com.
- WHO Pharmaceuticals Newsletter No. 3, 2003.
- Communication from the Spanish Medicines Agency, 8 Apr 2003. http://www.msc.es/ agemed/csmh/notas/astemizol.asp.
- Ministry may review sale of 12 ‘risky’ drugs,www.dnaindia.com.
- Berthet S, Olivier P, Montastruc JL, Mestre ML. Drug safety of rosiglitazone and pioglitazone in France: A study using the French PharmacoVigilance database. BMC Clinical Pharmacology 2011; 11:5.
- Ching CK, Lai CK, Poon WT, Wong NP, Yan WW, Chan AYW, Mak T WL. Hazards posed by a banned drug—phenformin is still hanging around. Hong Kong Med J 2008; 14.
- Marx R E, Sawatari D Y, Fortin M, Broumand V. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg 2005; 63:1567–75.
- Mudiganty SSP,Dang A,Rataboli PV.Crippled Pharmaco vigilance: A qualm of medical profession!. Journal of Clinical and Diagnostic Research 2008; 2:1110-1118.
- Ban on anti-anxiety drug Deanxit in pipeline. June 22, 2011.www.dailypioneer.com 28. Patwardhan B, Vaidya A, Chorghade M. Ayurveda and natural products drug discovery. Current Science 2004; 86.
- Shukla K & Jain V. Heavy metals in Ayurvedic Formulations-Safety Issues. The Pharmaceutical Magazine. Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (Dec 2006).
- Joshi TK. Ayurvedic medicines: Panacea or Poison,: expresspharmapulse.com 31. Dhaware D, Deshpande A, Khandekar R. N, Chowgule R, Gangal S. V. Study of lead and arsenic in ayurvedic medicines. Journal of Herbal Medicine and Toxicology 2011; 5:39-46.
- Parmar V. Herbal medicines: Its toxic effects and drug interactions. The Indian Anaesthetists’ Forum October 2005.
- Gogtay NJ, Kshirsagar NA. Call for Spontaneous Reports of Adverse Drug Events from Indian Physicians- Need of the Hour. J Assoc Physicians India 2007;55:597
Abstract Views: 429
PDF Views: 0